KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

Ozempic, Mounjaro and other weight loss drugs can have nasty side effects, and reducing the volume of food you eat will also ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Danish pharmaceutical company Novo Nordisk announced last weekend that Wegovy, the weight-loss version of the company's ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...